Bibliography
- Mahmood I , BalianJD. Interspecies scaling: a comparative study for the prediction of clearance and volume using two or more than two species. Life Sci.59, 579–585 (1996).
- Ling J , ZhouH, JiaoQ, DavisDM. interspecies scaling of therapeutic monoclonal antibodies: initial look. J. Clin. Pharmacol.49(12), 1382–1402 (2009).
- Wang W , PrueksaritanontT. Prediction of human clearance of therapeutic proteins: simple of allometric scaling method revisited. Biopharm. Drug Disp.31, 253–263 (2010).
- Mahmood I . Interspecies scaling of protein drugs: prediction of clearance from animals to humans. J. Pharm. Sci.93(1), 177–185 (2004).
- Mahmood I . Pharmacokinetic allometric scaling of antibodies: application of the first-in-human dose estimation. J. Pharm. Sci.98(10), 3850–3861 (2009).
- Adolph EF . Quantitative relations in the physiological constitutions of mammals. Science109(2841), 579–585 (1949).
- Gayon J . History of the concept of allometry. Amer. Zool.40, 748–758 (2000).
- Dedrick RL . Animal scale-up. J. Pharmacokinet. Biopharm.93(1), 435–461 (1973).
- Modenti J . Man versus beast: pharmacokinetic scaling in mammals. J. Pharm. Sci.75(11), 1028–1040 (1986).
- Teitelbaum Z , LaveT, FreijerJ, CohenAF. Risk assessment in extrapolation of pharmacokinetics from preclinical data to humans. Clin. Pharmacokinet.49(9), 619–632 (2010).
- Mahmood I , BalianJD. Interspecies scaling: predicting pharmacokinetic parameters of antiepileptic drug in humans from animals with special emphasis on clearance. J. Pharm. Sci.85(4), 411–414 (1996).
- Mahmood I , BalianJD. The pharmacokinetic principles behind scaling from preclinical results to Phase I protocols. Clin. Pharmacokinet.36(1), 1–11 (1999).
- Mahmood I , GreenMD, FisherJE. Selection of the first-time dose in humans: comparison of different approaches based on interspecies scaling of clearance. J. Clin. Pharmacol.43(7), 692–697 (2003).
- Mahmood I , BalianJD. Interspecies scaling: predicting clearance of drugs in humans. Three different approaches. Xenobiotica26(9), 887–895 (1996).
- Mordenti J , ChenSA, MooreJA, FerraioloBL, GreenJD. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pham. Res.8(11), 1351–1359 (1991).
- Kuester K , KloftC. Part II, Chapter 3. Pharmacokinetics of monoclonal antibodies. In: Pharmacokinetics and Pharmacodynamics of Biotech Drugs. Meibohm B (Ed.). Wiley-VCH, Weinheim, Germany 45–91 (2006).
- Tabrizi MA , Tseng C-ML, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today11(1/2), 81–88 (2006).
- Karanikas G , Ulrich-PurH, BechererAet al. Uptake of indium-111-labeled human polyclonal immunoglobulin G in pancreatic cancer: in vivo and in vitro studies. Oncol. Rep. 9(2), 353–357 (2002).
- Lin YS , NguyenC, MendozaJLet al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288(1), 371–378 (1999).
- Vugmeyster Y , SzklutP, TchistiakovaL, AbrahamW, KasaianM, XuX. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms. Int. Immunopharmacol.8(3), 477–483 (2008).
- Wang W , WangEQ, BalthasarJP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther.84(5), 548–558 (2008).
- Mould D , BreenB. Pharmacokinetics and pharmacodynamics of monoclonal antibodies. Biodrugs24(1), 23–39 (2010).
- Zhu X , MengG, DickinsonBLet al. MHC Class I-related neonatal Fc receptor for IgG is unctionally expressed in monocytes, intestinal macrophages and dendritic cells. J. Immunol. 166(5), 3266–3276 (2001).
- Brambell FWR , HallidayR, MorrisIGet al. Theoretical model of γ-globulin catabolism. Nature 203(4952), 1352–1355 (1964).
- Brambell FWR . The transmission of immunity from mother to young and the catabolism of immunoglobulins. Lancet288(7473), 1087–1093 (1966).
- Spiegelberg HL , WeigleWO. The catabolism of homologous and heterologous 7S gamma globulin fragments. J. Exp. Med.121(3), 323–338 (1965).
- Datta-Mannan A , WitcherDR, TangY, WatkinsJ, JiangW, WroblewskiVJ. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos.35(1), 86–94 (2007).
- Roopenian DC , AkileshS. FcRn: the neonatal Fc receptor comes of age. Nat. Rev.7(9), 715–725 (2007).
- Datta-Mannan A , WitcherDR, TangY, WatkinsJ, WroblewskiVJ. Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor. J. Biol. Chem.282(3), 1709–1717 (2007).
- Hinton PR , XiongJM, JohlfsMG, TangMT, KellerS, TsurushitaN. An engineered human IgG1 antibody with longer serum half-life. J. Immunol.176(1), 346–356 (2006).
- Kenanova VE , OlafsenT, AndersenJT, SandlieI, WuAM. Engineering of the Fc region for improved PK (FcRn Interaction). In: Antibody Engineering. Kontermann R, Dübel S (Eds). Springer, NY, USA, Chapter 27, 411–430 (2010).
- Zalevsky J , ChamberlainAK, HortonHMet al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28(2), 157–159 (2010).
- Ober RJ , RaduCG, GhetieV, WardES. Differences in promiscuity for antibody–FcRn interactions across species: implications for therapeutic antibodies. Int. Immunol.13(12), 1551–1559 (2001).
- Andersen JT , DabaMB, BerntzenG, MichaelsenTE, SandlieI. Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding. J. Biol. Chem.285(7), 4826–4836 (2010).
- Wileman T , HardingC, StahlP. Receptor-mediated endocytosis. Biochem. J.232(1), 1–14 (1985).
- Ng CM , BaiS, TakimotoCH, TangMT, TolcherAW. Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-a5b1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer. Chemother. Pharmacol.65(2), 207–217 (2009).
- Dong JQ , SalingerDH, EndresCJet al. Predicting human pharmacokinetics of monoclonal antibodies with linear and non-linear elimination based only on monkey data. NBC09–000353 poster presented at National Biotech Conference, Seattle, WA, USA 21–24 June 2009.
- Bauer RJ , DedrickRL, WhiteML, MurrayMJ, GarovoyMR. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm.27(4), 397–420 (1999).
- Fridman W . Fc receptors and immunoglobulin binding factors. FASEB J.5(12), 2684–2690 (1991).
- Nimmerjahn F , RavetchJV. Fcγ receptors: Old friends and new family members. Immunity24(1), 19–28 (2006).
- Nimmerjahn F , RavetchJV. Fcγ receptors as regulators of immune response. Nat. Rev. Immunol.8(1), 34–47 (2008).
- Reddy MP , KinneyCA, ChaikinMAet al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 164(4), 1925–1933 (2000).
- Uchida J , HamaguchiY, OliverJAet al. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. J. Exp. Med. 199(12), 1659–1669 (2004).
- Rogers KA , ScinicarielloF, AttanasioR. IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J. Immunol.177(6), 3848–3856 (2006).
- Schellekens H . Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther.24(11), 1720–1740 (2002).
- Shankar G , PendleyC, SteinKE. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat. Biotechnol.25(5), 555–561 (2007).
- Poston RS , RobbinsRC, ChanBet al. Effects of humanized monoclonal antibody to rhesus CD11a in rhesus monkey cardiac allograft recipients. Transplantation 69(10), 2005–2013 (2000).
- Rojas JR , TaylorRP, CunninghamMRet al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. JPET 313(2), 578–585 (2005).
- Harris RJ , WagnerKL, SpellmanMW. Structural characterization of a recombinant CD4–IgG hybrid molecule. Eur. J. Biochem.194(2), 611–620 (1990).
- Ducongé J , Fernández-SánchezE, AlvarezD. Interspecies scaling of the monoclonal anti-EGF receptor IOR EGF/r3 antibody disposition using allometric paradigm: is it really suitable? Biopharm. Drug. Dispos.25(4), 177–186 (2004).
- Deng R , IyerS, Theil F-P, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data. What have we learned? MAbs3(1), 1–6 (2011).
- Ward KW , SmithBR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab. Dispos.32(6), 603–611 (2004).
- Ward KW , SmithBR. A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab. Dispos.32(6), 612–619 (2004).
- Mager DE , JuskoWJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J. Pharmacokinet. Pharmacodyn.28(6), 507–532 (2001).
- Mager DE , KrzyzanskiW. Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Pharm. Res.22(10), 1589–1596 (2005).